PDT Partners’s Cytek Biosciences CTKB Stock Holding History

PDT Partners’s Portfolio CTKB Stock Details CTKB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$380K	Sell	86,869 -5,000	-5%	-$23.6K	0.02%	443
2025 Q4	$464K	Hold	91,869	–	–	0.03%	433
2025 Q3	$319K	Hold	91,869	–	–	0.02%	505
2025 Q2	$312K	Sell	91,869 -42,196	-31%	-$141K	0.02%	590
2025 Q1	$538K	Buy	+134,065	New	+$695K	0.04%	517
2023 Q3	–	Sell	-115,545	Closed	-$987K	–	605
2023 Q2	$987K	Buy	115,545 +34,254	+42%	+$307K	0.14%	253
2023 Q1	$747K	Buy	81,291 +49,910	+159%	+$537K	0.1%	323
2022 Q4	$320K	Sell	31,381 -55	-0.2%	-$739	0.05%	472
2022 Q3	$463K	Sell	31,436 -14,732	-32%	-$191K	0.07%	455
2022 Q2	$495K	Buy	46,168 +26,733	+138%	+$266K	0.04%	605
2022 Q1	$210K	Buy	+19,435	New	+$262K	0.02%	807

Other funds holding CTKB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

PDT Partners's CTKB Position: Q1 2026 in Review

PDT Partners reduced its Cytek Biosciences (CTKB) stake by 5.4% in Q1 2026, selling an estimated $23.6K and leaving 86,869 shares worth $380K. The position accounts for 0.02% of the portfolio, ranked #443.

PDT Partners first reported a position in CTKB in Q1 2022 and has held it in 11 quarters since. The position peaked at $987K in Q2 2023. 165 funds tracked by Wall St. Rank hold CTKB as of Q1 2026.

PDT Partners held 86,869 shares of Cytek Biosciences worth $380K as of Q1 2026.
PDT Partners sold 5,000 Cytek Biosciences shares in Q1 2026, an estimated $23.6K.
Cytek Biosciences made up 0.02% of PDT Partners's portfolio in Q1 2026, its #443 holding.
PDT Partners first reported a position in Cytek Biosciences in Q1 2022 and has held it in 11 quarters since.
PDT Partners's Cytek Biosciences position peaked at $987K in Q2 2023.
165 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2026.

Based on PDT Partners's 13F filing for Q1 2026, filed 15 May 2026.